Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Br J Cancer
2005 May 09;929:1644-9. doi: 10.1038/sj.bjc.6602573.
Show Gene links
Show Anatomy links
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
De Vita F
,
Orditura M
,
Matano E
,
Bianco R
,
Carlomagno C
,
Infusino S
,
Damiano V
,
Simeone E
,
Diadema MR
,
Lieto E
,
Castellano P
,
Pepe S
,
De Placido S
,
Galizia G
,
Di Martino N
,
Ciardiello F
,
Catalano G
,
Bianco AR
.
???displayArticle.abstract???
The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m(-2) on day 1, FA 200 mg m(-2) as a 2 h infusion followed by bolus 5-FU 400 mg m(-2) and a 22 h infusion of 5-FU 600 mg m(-2), repeated for 2 consecutive days every 2 weeks. All patients were assessable for toxicity and response to treatment. Four (7%) complete responses and 19 partial responses were observed (overall response rate, 38%). Stable disease was observed in 22 (36%) patients, with progressive disease in the other six (10%) patients. Median time to progression (TTP) and median overall survival (OS) were 7.1 and 11.2 months, respectively. National Cancer Institute Common Toxicity Criteria grade 3 and 4 haematologic toxicities were neutropenia, anaemia and thrombocytopenia in 36, 10 and 5% of the patients, respectively. Grade 3 peripheral neuropathy was recorded in three (5%) patients. FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer.
Figure 1. Estimated 21-month cumulative probability of survival and time to treatment progression in 61 AGC patients. Shown are TTP (□□□□□□) and OS (▪▪▪▪▪) in the 61 AGC patients treated with the FOLFOX-4 regimen.
Figure 2. Estimated 21-month cumulative probability of survival in 61 AGC patients. Shown are OS in the 36 AGC patients treated with second-line chemotherapy (□□□□□□) and in the 25 patients treated with best supportive care (○○○○○) following disease progression. The figure also depicts OS in the 61 patients (▪▪▪▪▪).
Ajani,
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
2002, Pubmed
Ajani,
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
2002,
Pubmed
Al-Batran,
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
2004,
Pubmed
Alberts,
Gastric cancer: epidemiology, pathology and treatment.
2003,
Pubmed
Blot,
Rising incidence of adenocarcinoma of the esophagus and gastric cardia.
1991,
Pubmed
Bécouarn,
Oxaliplatin: available data in non-colorectal gastrointestinal malignancies.
2001,
Pubmed
Caussanel,
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
1990,
Pubmed
Eriguchi,
A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines.
2003,
Pubmed
Extra,
Phase I study of oxaliplatin in patients with advanced cancer.
1990,
Pubmed
Giuliani,
Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.).
2003,
Pubmed
Glimelius,
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
1997,
Pubmed
Kelsen,
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
1992,
Pubmed
Kim,
Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.
2003,
Pubmed
Kim,
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
1993,
Pubmed
Lacave,
Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial.
1991,
Pubmed
Louvet,
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
2002,
Pubmed
Lévi,
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
1992,
Pubmed
Lévi,
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
1994,
Pubmed
Murad,
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
1993,
Pubmed
Parkin,
Epidemiology of cancer: global patterns and trends.
1998,
Pubmed
Pyrhönen,
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
1995,
Pubmed
Raymond,
Oxaliplatin: a review of preclinical and clinical studies.
1998,
Pubmed
Rougier,
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.
1994,
Pubmed
Simon,
Optimal two-stage designs for phase II clinical trials.
1989,
Pubmed
Vanhoefer,
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
2000,
Pubmed
Webb,
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
1997,
Pubmed
Wils,
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
1991,
Pubmed
de Gramont,
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
2000,
Pubmed
